Revotar Biopharmaceuticals AG has been awarded funding of the German Federal Ministry of Education and Research
The project is headed by Gerhard Wolff, M.D., Vice President R&D of Revotar, assisted by Ewald Aydt, Ph.D., Director Discovery of Revotar. The project is a significant contribution to Revotar`s strategy to develop selectin antagonists as small molecule drugs (SMD) for inflammatory diseases, stated Stephan Tarlach, CEO of Revotar. In addition, the awarded funding reflects the contineously growing confidence in the business concept of Revotar, added Marc Voigt, CFO of Revotar.
Most read news
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.